Targeting Nrf2 and its downstream genes, including NQO1, could provide potential benefits for the management of AD through the activation of antioxidant genes, the suppression of microglia-mediated inflammation, and the promotion of mitochondrial function [130]. Here, NFE2L2 is linked to Alzheimer disease.